Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Infectious Disease · Hansen's disease

Life After Treatment: Protecting Your Nerves and Your Mind

At a Glance

After completing treatment for Hansen's disease, the bacteria are cured but nerve damage often remains. You must protect insensitive hands and feet with daily inspections, moisturize dry skin, and remain vigilant for late immune reactions that require prompt medical care.

Finishing your course of antibiotics is a major milestone, but for many, it is not the end of the journey. While the multidrug therapy (MDT) kills the bacteria, the damage those bacteria caused to your nerves may be long-lasting or even permanent [1][2]. Transitioning from “patient” to “survivor” means learning to live safely with neuropathy (nerve damage) and protecting your mental well-being from the weight of historical stigma [3][4].

Protecting Your “Insensitive” Limbs

When nerves are damaged, they lose the ability to send pain signals. This is called anesthesia [5]. Pain is actually a protective mechanism; without it, a small pebble in your shoe or a hot plate can cause a severe injury without you realizing it [6][7].

To prevent ulcers and infections, you must become your own “pain alarm” through a daily self-care routine [6]:

  • The Daily Inspection: Every night, use a mirror to look at the soles of your feet and the palms of your hands. Look for redness, swelling, blisters, or even small scratches [7][8].
  • Soak and Seal: Nerve damage can stop your skin from sweating, making it dry and prone to cracking. Soak your feet in plain water for 20 minutes daily, then apply a thick moisturizer or oil (like petroleum jelly) while the skin is still damp to “seal” in the moisture [7][6].
  • Protective Gear: Never walk barefoot, even at home. Wear well-fitting, supportive shoes and use gloves when handling hot objects, gardening, or using tools [6][8].
  • Eye Care: If the nerves in your face are affected, you may not blink as often or close your eyes fully while sleeping. Use “artificial tears” during the day and consider eye ointment at night to prevent the surface of the eye (the cornea) from drying out and scarring [1][2].

Informing Future Healthcare Providers

You must actively inform any future doctors—especially podiatrists, physical therapists, and ophthalmologists—of your Hansen’s disease history [5]. Even decades later, this information is crucial for them to provide you with the correct preventive care for ‘silent’ or late-onset neuropathy [9].

Managing the Psychological Toll

The word “leprosy” carries centuries of unearned shame. Many patients experience “stigma-related distress,” leading to anxiety, depression, or a desire to isolate themselves from others [3][10].

  • Reclaiming Your Identity: Using the term Hansen’s disease is a powerful way to distance yourself from ancient myths and align with the modern medical reality of your condition [11][12].
  • Addressing Discoloration: If you took clofazimine, your skin may still have a “bronzed” or darkened tint [13]. Because this drug stays in your body fat for a long time, it can take several months—or even more than a year—for your natural skin tone to fully return [14][15]. Understanding that this is a temporary side effect of a life-saving drug can help you manage social interactions during this time [16].
  • Seeking Support: You do not have to carry this alone. Counseling and support groups—ideally those that focus on chronic illness or infectious disease—can help you process the trauma of diagnosis and improve your quality of life [17][18].

Vigilance After the Cure

Even after your antibiotics are finished, you must remain alert for late reactions. These are immune system flare-ups that can happen months or even years later, causing sudden new pain or weakness [19][20]. If you notice any “silent” changes—like your grip becoming weaker or your toes starting to curl—contact your specialist immediately [5][21]. Ongoing monitoring is the key to maintaining your independence and health for years to come [9][22].

Common questions in this guide

Will my nerves recover after finishing Hansen's disease treatment?
While multidrug therapy cures the bacterial infection, the nerve damage caused by the disease may be long-lasting or permanent. You will need to learn how to live safely with neuropathy and protect your limbs from everyday injuries you might not feel.
How can I protect my hands and feet if I have lost feeling in them?
Inspect your hands and feet daily with a mirror for cuts or blisters. Soak your feet in water, apply a thick moisturizer to prevent cracking, and always wear protective gear like well-fitting shoes and work gloves.
How long will it take for my skin color to return to normal after taking clofazimine?
Clofazimine can cause a temporary bronzed or darkened skin tint because the drug stays in your body fat. It can take several months to over a year after finishing treatment for your natural skin tone to fully return.
What are late reactions in Hansen's disease?
Late reactions are immune system flare-ups that can occur months or years after you finish treatment. They can cause sudden new pain, muscle weakness, or nerve changes, and they require immediate medical attention to prevent further damage.
How should I care for my eyes if Hansen's disease affected my face?
If nerve damage prevents you from blinking normally or closing your eyes completely, use artificial tears during the day. You may also need to use eye ointment at night to prevent your cornea from drying out and scarring.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my history of nerve involvement, what is my long-term risk for progressive neuropathy now that treatment is finished?
  2. 2.Can you refer me to a physical or occupational therapist who specializes in 'insensitive' limb care?
  3. 3.Are my eyes closing completely? Do I need to use specialized eye drops or nighttime taping to prevent corneal damage?
  4. 4.How often should I return for follow-up exams to monitor for 'silent' neuropathy or late-onset reactions?
  5. 5.Is there a mental health professional you recommend who has experience with patients facing chronic illness and social stigma?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Bilateral corneal perforation caused by neurotrophic keratopathy associated with leprosy: a case report.

    Iraha S, Kondo S, Yamaguchi T, Inoue T

    BMC ophthalmology 2022; (22(1)):42 doi:10.1186/s12886-022-02265-6.

    PMID: 35093062
  2. 2

    Evaluation of proposed cranial and maxillary bone alteration parameters in persons affected by Hansen's disease.

    do Espírito Santo RB, Gonçalves DVC, Serafim RA, et al.

    PLoS neglected tropical diseases 2021; (15(8)):e0009694 doi:10.1371/journal.pntd.0009694.

    PMID: 34432803
  3. 3

    Leprosy and lymphatic filariasis-related disability and psychosocial burden in northern Mozambique.

    van Wijk R, Raimundo L, Nicala D, et al.

    PLoS neglected tropical diseases 2024; (18(8)):e0012342 doi:10.1371/journal.pntd.0012342.

    PMID: 39137215
  4. 4

    Relationship between social participation and stigma in people affected by leprosy: A cross-sectional study in northeastern Brazil.

    Lima MCV, de Arruda GA, Alves MGT, et al.

    Belitung nursing journal 2026; (12(1)):49-57 doi:10.33546/bnj.4193.

    PMID: 41585842
  5. 5

    Unmasking Carpal Tunnel Syndrome by High-Resolution Ultrasonography in Misdiagnosed Pure Neuritic Leprosy: A Case Report.

    Dalave K, Patil P, Raman T, Agarwal U

    Cureus 2024; (16(7)):e65578 doi:10.7759/cureus.65578.

    PMID: 39192940
  6. 6

    A Randomized Controlled Study Comparing the Efficacy of Autologous Smashed Follicular Dermal Graft and Epidermal Cell Suspension versus Normal Saline Dressing in the Treatment of Chronic Nonhealing Trophic Ulcers in Patients with Hansen's Disease.

    Dheemant M, Harikishan KY, Naveen S, Belliappa PR

    Journal of cutaneous and aesthetic surgery 2023; (16(2)):90-100 doi:10.4103/JCAS.JCAS_9_21.

    PMID: 37554673
  7. 7

    Autonomic neuropathy impairing quality of life after completion of MDT: Are we managing enough?

    Anand V, Pradhan S, Kumar P

    Leprosy review 2016; (87(2)):239-42.

    PMID: 30212169
  8. 8

    Treatment and Evaluation Advances in Leprosy Neuropathy.

    Ebenezer GJ, Scollard DM

    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2021; (18(4)):2337-2350 doi:10.1007/s13311-021-01153-z.

    PMID: 34799845
  9. 9

    Prevalence of Disability and Associated Factors among Registered Leprosy Patients in All Africa Tb and Leprosy Rehabilitation and Training Centre (ALERT), Addis Ababa, Ethiopia.

    Shumet T, Demissie M, Bekele Y

    Ethiopian journal of health sciences 2015; (25(4)):313-20 doi:10.4314/ejhs.v25i4.4.

    PMID: 26949295
  10. 10

    A Clinicoepidemiological Study of Psychiatric Co-Morbidity in Hansen's Disease.

    Rani R, Tegta GR, Verma GK, et al.

    Indian dermatology online journal 2021; (12(6)):847-851 doi:10.4103/idoj.IDOJ_141_21.

    PMID: 34934720
  11. 11

    Why we should stop using the word leprosy.

    Deps P, Cruz A

    The Lancet. Infectious diseases 2020; (20(4)):e75-e78 doi:10.1016/S1473-3099(20)30061-X.

    PMID: 32135079
  12. 12

    Consensus in Brazil on the renaming of leprosy to Hansen's disease.

    Delboni L, Deps P

    Transactions of the Royal Society of Tropical Medicine and Hygiene 2021; (115(9)):1086-1087 doi:10.1093/trstmh/trab115.

    PMID: 34302735
  13. 13

    The Physicochemical Basis of Clofazimine-Induced Skin Pigmentation.

    Murashov MD, LaLone V, Rzeczycki PM, et al.

    The Journal of investigative dermatology 2018; (138(3)):697-703 doi:10.1016/j.jid.2017.09.031.

    PMID: 29042210
  14. 14

    Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.

    Swanson RV, Ammerman NC, Ngcobo B, et al.

    Antimicrobial agents and chemotherapy 2016; (60(5)):2864-9 doi:10.1128/AAC.00177-16.

    PMID: 26926638
  15. 15

    Quantifying the Reversibility of Clofazimine-induced Pigmentation in a Patient with Mycobacterium abscessus Pulmonary Disease.

    Ito M, Watanabe F, Furuuchi K, et al.

    Internal medicine (Tokyo, Japan) 2025; (64(12)):1884-1887 doi:10.2169/internalmedicine.4498-24.

    PMID: 39566985
  16. 16

    Clofazimine-induced cutaneous hyperpigmentation as a source of stigma in the treatment of leprosy: A cross-sectional study.

    Nogueira AS, Garcia MAC, Silva MBD, et al.

    Tropical medicine & international health : TM & IH 2024; (29(4)):327-333 doi:10.1111/tmi.13977.

    PMID: 38348585
  17. 17

    Task sharing for the management of leprosy by nurses in a tertiary healthcare setting of Northern India.

    Pratibha , Kavita , Mehta H, et al.

    Transactions of the Royal Society of Tropical Medicine and Hygiene 2024; (118(6)):376-383 doi:10.1093/trstmh/trad101.

    PMID: 38240067
  18. 18

    The Impact of a Rights-Based Counselling Intervention to Reduce Stigma in People Affected by Leprosy in Indonesia.

    Lusli M, Peters R, van Brakel W, et al.

    PLoS neglected tropical diseases 2016; (10(12)):e0005088 doi:10.1371/journal.pntd.0005088.

    PMID: 27959932
  19. 19

    Clinical Pearls: Leprosy Reactions.

    Wu J, Boggild AK

    Journal of cutaneous medicine and surgery 2016; (20(5)):484-5 doi:10.1177/1203475416644832.

    PMID: 27060010
  20. 20

    Evaluation of Myelin Sheath Marker Krox-20 for Detection of Early Disability in Leprosy.

    Widasmara D, Agusni I, Turchan A

    Indian journal of leprosy 2016; (88(2)):105-110.

    PMID: 29757542
  21. 21

    Neuritic Leprosy; An Intriguing Re-visit to a Forbidden Ailment.

    Shrestha BK, Ranabhat K, Pant R, et al.

    Kathmandu University medical journal (KUMJ) 2019; (17(65)):73-76.

    PMID: 31734684
  22. 22

    Determinant factors of leprosy-related disability; comparison of acceleration failure time and parametric shared frailty models.

    Masresha BM, Yesuf KM, Moyehodie YA, et al.

    PloS one 2023; (18(4)):e0271883 doi:10.1371/journal.pone.0271883.

    PMID: 37011051

This page provides educational information on managing life after Hansen's disease treatment. It does not replace professional medical advice. Always consult your healthcare provider or specialist for personalized care.

Get notified when new evidence is published on Leprosy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.